In the last decade, there has been minimal progress toward an improved prognosis for patients with SCLC. Circulating tumour cells (CTCs) are an accessible liquid biopsy. They can be used to generate CTC derived explants (CDXs), clinically relevant models that might mirror patient response to therapeutics. Vickers et al. conducted a single-centre retrospective analysis of patients with SCLC who had at least one blood sample taken for the discovery and validation of novel biomarkers .
Paired blood samples were used for CTC enumeration with CellSearch Technology and for the generation of CDX models. Demographic and clinical data were analysed for differences between patients whose blood samples generated a CDX and those whose samples did not. A total of 231 paired blood samples were taken from 147 patients; 45 CDXs were generated from 34 patients. CTC number was higher in samples with a CDX than in those without a CDX (P=0.001). Successful progression samples had a lower C...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Entrectinib treatment in patients with *ROS1*+ NSCLC Next Article
Spread through air spaces is prognostic in lung neuroendocrine tumours »
Table of Contents: WCLC 2018
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.